U.S. Supreme Court rebuffs Novartis, allows generic versions of MS drug

Yichang Hec Changjiang Pharmaceutical Co

13/10/2022 22:12

Oct 13 (Reuters) - The U.S. Supreme Court on Thursday
turned down Novartis Pharmaceuticals Corp's  NOVN.S  bid to
block the launch of generic versions of the company's
blockbuster multiple sclerosis drug Gilenya in a dispute with
China's HEC Pharm Co Ltd  1558.HK  and other generic drugmakers.
    Novartis had asked the justices to stay a lower court's
ruling that lifted a ban on generic versions of Gilenya, the
Switzerland-based company's third highest-selling drug last year
with $2.8 billion in sales.
 (Reporting by Nate Raymond in Boston
Editing by Chris Reese)
 ((Nate.Raymond@thomsonreuters.com and Twitter @nateraymond;
347-243-6917; Reuters Messaging:
nate.raymond.thomsonreuters.com@reuters.net))